Lidocaine Infusion: An Analgesic Option for Checkpoint Inhibitor Arthritis: A Case Report

Abstract

This report describes the use of subcutaneous lidocaine infusion to manage complex pain associated with checkpoint inhibitor inflammatory arthritis. In addition, the safe administration of lidocaine in the home setting is described. A 49-year-old man with metastatic melanoma to lung, right axilla and posterior chest wall on regular pembrolizumab developed checkpoint inhibitor inflammatory arthritis. Pain associated with this was unresponsive to simple analgesia, escalating opioids and adjuvant analgesics. Lidocaine infusion was used on separate occasions (inpatient unit and home setting) to gain rapid and sustained control of inflammatory pain. Inflammatory pain responded well to 2 mg/kg/h lidocaine infusion over 4 days with sustained response between infusions of up to 6 wk. Resulting in improved mobility, functional status, and overall quality of life. Lidocaine infusion should be considered as an option for analgesic management of checkpoint inhibitor inflammatory arthritis in patients for whom usual treatment is ineffective, and as an opioid-sparing intervention.

Keywords:

• Lidocaine
• checkpoint inhibitor
• analgesia
• arthritis

Disclosure statement

The authors declare no conflicts of interest.

Patient consent

The report follows the Waikato District Health Board policy and documentation on patient consent. Written consent to write and publish this report was sought from the patient.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.